北陆药业(300016) - 2021 Q1 - 季度财报

Financial Performance - Revenue for Q1 2021 reached ¥222,075,960.67, an increase of 76.56% compared to ¥125,780,404.40 in the same period last year[8] - Net profit attributable to shareholders was ¥50,451,938.09, up 88.36% from ¥26,784,624.69 year-on-year[8] - Basic earnings per share increased by 91.11% to ¥0.1032 from ¥0.0540 in the previous year[8] - The company achieved operating revenue of 222.08 million yuan, a year-on-year increase of 76.56%[19] - The net profit attributable to shareholders reached 50.45 million yuan, up 88.36% year-on-year[22] - The company reported a total profit of ¥52,293,902.63 for Q1 2021, an increase of 68.0% from ¥31,098,889.25 in Q1 2020[59] - Net profit for Q1 2021 was ¥45,325,558.55, representing a 78.6% increase from ¥25,380,232.35 in Q1 2020[59] - Total operating revenue for Q1 2021 reached ¥222,075,960.67, a significant increase of 76.6% compared to ¥125,780,404.40 in the same period last year[57] - Earnings per share (EPS) for Q1 2021 were reported at ¥0.1032, compared to ¥0.0540 in the previous year[59] Cash Flow and Investments - The net cash flow from operating activities decreased by 13.51% to ¥47,200,999.98 compared to ¥54,574,319.53 in the same period last year[8] - Operating cash inflow from sales increased to ¥231,776,895.70, up from ¥188,819,097.51, representing a growth of approximately 22.8% year-over-year[65] - Total cash outflow from investment activities surged to ¥455,085,433.08, compared to ¥31,153,923.76 in the previous period, indicating a significant increase in investment spending[67] - Net cash flow from investment activities was negative at -¥424,149,576.66, worsening from -¥24,754,722.16 year-over-year[67] - Cash and cash equivalents at the end of the period stood at ¥615,431,981.12, down from ¥299,439,473.63, reflecting a decrease of approximately 51.3%[67] - Cash inflow from other investment activities reached ¥30,000,000.00, a substantial increase from ¥6,000,000.00 in the previous period[67] - Cash outflow for purchasing goods and services rose to ¥78,120,254.56, compared to ¥38,007,971.24, marking an increase of about 105.5%[65] - Cash paid to employees increased to ¥41,913,377.35 from ¥32,911,971.60, representing a rise of approximately 27.3%[65] - Cash flow from financing activities was negative at -¥3,438,433.51, compared to a positive inflow of ¥14,976,116.33 in the previous period[67] - The company experienced a net decrease in cash and cash equivalents of -¥380,359,746.45, contrasting with an increase of ¥44,831,634.87 in the prior period[67] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,869,515,216.74, a slight increase of 0.77% from ¥2,847,573,506.75 at the end of the previous year[8] - Total liabilities decreased from ¥955,500,130.72 to ¥931,351,066.02, a reduction of approximately 2.3%[47] - Total equity increased from ¥1,892,073,376.03 to ¥1,938,164,150.72, reflecting a growth of about 2.4%[49] - The company's total assets amounted to approximately CNY 2.87 billion, an increase from CNY 2.85 billion at the end of 2020[43] - The company's cash and cash equivalents decreased to CNY 631.14 million from CNY 1.01 billion at the end of 2020, reflecting a decline of approximately 37.8%[43] - The total current assets increased slightly to CNY 1.36 billion from CNY 1.35 billion, showing a growth of about 1%[43] - The company's accounts receivable rose to CNY 181.56 million, up from CNY 170.31 million, indicating an increase of approximately 6.9%[43] - Total assets increased from ¥2,300,416,515.10 to ¥2,356,163,536.39, a growth of about 2.4%[55] - The company's total equity attributable to shareholders rose from ¥1,741,905,282.13 to ¥1,793,106,642.12, an increase of approximately 2.9%[49] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 32,652[12] - The largest shareholder, Wang Daixue, holds 22.38% of the shares, totaling 110,683,213 shares[12] - The company’s major shareholder, Mr. Wang Daixue, reduced his holdings of convertible bonds on January 21, 2021[31] - The company’s major shareholder has pledged an additional 9,500,000 shares to Anxin Securities on April 23, 2021[31] Research and Development - Research and development expenses increased to ¥14,195,503.14, up 23.5% from ¥11,481,284.90 year-over-year[57] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[57] - The company has initiated the construction of a new contrast agent production line to ensure quality and supply[25] - The company plans to expand production capacity with the new 850-ton iodine contrast agent project, which has passed GMP compliance checks[24] - The company’s iodinated contrast agent injection has passed the consistency evaluation for generic drugs on April 20, 2021[31] - The company’s subsidiary, Zhejiang Haichang Pharmaceutical Co., Ltd., has completed GMP compliance inspections for its production lines[31] Financial Expenses - The company reported a significant increase in financial expenses, totaling 5.87 million yuan, up 427.44% year-on-year, mainly due to convertible bond provisions[20] - The company’s financial expenses rose to ¥5,873,411.93, compared to a negative expense of -¥1,793,745.99 in the previous year[57] - The investment income from associates and joint ventures was ¥266,871.23, a recovery from a loss of -¥660,786.13 in the same period last year[59]